Straits Times Index
3,187.66 +32.97 (+1.05%) S&P 500
5,009.69 -12.52 (-0.25%) Dow
37,764.18 +10.87 (+0.03%) Nasdaq
15,600.47 -82.90 (-0.53%) Bitcoin USD
63,407.32 +2,241.48 (+3.66%) CMC Crypto 200
885.54 0.00 (0.00%)
GILD Jun 2024 120.000 call
| Previous close | 0.0500 |
| Open | 0.0700 |
| Bid | 0.0000 |
| Ask | 2.2400 |
| Strike | 120.00 |
| Expiry date | 2024-06-21 |
| Day's range | 0.0500 - 0.0700 |
| Contract range | N/A |
| Volume | |
| Open interest | 4 |
ZacksAnalysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PR NewswireGILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO INNOVATIVE INITIATIVES IN ASIA
Gilead Sciences, Inc. (Nasdaq: GILD), announced a global distribution of US$4 million through its ALL4LIVER Grant ("Grant") to support community-backed innovative projects associated with hepatitis B (HBV), hepatitis C (HCV), and hepatitis D (HDV). An official announcement was made at a Gilead-hosted symposium titled "Partnering for Global Health Equity: Case Studies from Around the World," held during the World Hepatitis Summit ("Summit") in Lisbon.
ZacksXilio's (XLO) Shares Surge 79.8% in a Month: Here's Why
Xilio (XLO) rallies 79.8% in a month on an exclusive global licensing agreement with Gilead Sciences to develop XTX301 for advanced solid tumors.
